Events

Precigen discussed the recent approval of the first and only FDA-approved therapy for the treatment of adults with recurrent respiratory papillomatosis (RRP).

Host: Jennifer Kim, Biotech Analyst, Cantor Participants: Helen Sabzevari, PhD, President and CEO, Precigen and Phil Tennant, Chief Commercial Officer, Precigen

Note: This event is for institutional clients of Cantor only - Please contact your Cantor Sales representative if interested in participating.